The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells
One of the major limits of chemotherapy is depending on the ability of the cancer cells
to elude and adapt to dierent drugs. Recently, we demonstrated how the activation of the M2
muscarinic receptor could impair neuroblastoma cell proliferation. In the present paper, we investigate
the possible eects mediated by the preferential M2 receptor agonist arecaidine propargyl ester (APE)
on drug resistance in two neuroblastoma cell lines, SK-N-BE and SK-N-BE(2C), a sub-clone presenting